- Home
- COMM vs PHVS Comparison
COMM vs PHVS Comparison
Compare COMM & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COMM
- PHVS
- Stock Information
- Founded
- COMM 1976
- PHVS 2015
- Country
- COMM United States
- PHVS Switzerland
- Employees
- COMM N/A
- PHVS N/A
- Industry
- COMM Radio And Television Broadcasting And Communications Equipment
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- COMM Technology
- PHVS Health Care
- Exchange
- COMM Nasdaq
- PHVS Nasdaq
- Market Cap
- COMM 1.8B
- PHVS 980.9M
- IPO Year
- COMM 2013
- PHVS 2021
- Fundamental
- Price
- COMM $7.36
- PHVS $22.99
- Analyst Decision
- COMM Hold
- PHVS Buy
- Analyst Count
- COMM 5
- PHVS 6
- Target Price
- COMM $4.88
- PHVS $37.17
- AVG Volume (30 Days)
- COMM 5.9M
- PHVS 59.1K
- Earning Date
- COMM 08-07-2025
- PHVS 08-13-2025
- Dividend Yield
- COMM N/A
- PHVS N/A
- EPS Growth
- COMM N/A
- PHVS N/A
- EPS
- COMM 3.42
- PHVS N/A
- Revenue
- COMM $4,417,100,000.00
- PHVS N/A
- Revenue This Year
- COMM $21.14
- PHVS N/A
- Revenue Next Year
- COMM $8.73
- PHVS N/A
- P/E Ratio
- COMM $2.15
- PHVS N/A
- Revenue Growth
- COMM 16.19
- PHVS N/A
- 52 Week Low
- COMM $1.47
- PHVS $11.51
- 52 Week High
- COMM $8.67
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- COMM 60.28
- PHVS 67.31
- Support Level
- COMM $7.34
- PHVS $17.63
- Resistance Level
- COMM $8.67
- PHVS $26.33
- Average True Range (ATR)
- COMM 0.39
- PHVS 1.70
- MACD
- COMM -0.09
- PHVS 0.65
- Stochastic Oscillator
- COMM 40.60
- PHVS 65.24
About COMM CommScope Holding Company Inc.
CommScope Holding Co Inc is a provider of infrastructure solutions for communication, data center, and entertainment networks. The company provides solutions for wired and wireless networks to enable service providers, including cable, telephone, data center, and digital broadcast satellite operators and media programmers, to deliver media, voice, Internet Protocol (IP) data services, and Wi-Fi to their subscribers and allow enterprises to experience constant wireless and wired connectivity across complex and varied networking environments. The company's operating segments are: Connectivity and Cable Solutions (CCS), Networking, Intelligent Cellular and Security Solutions (NICS), and Access Network Solutions (ANS).
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.